A registrational Phase II/III trial of VCN-01 in pediatric patients with advanced retinoblastoma

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 13 May 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2024 According to a Theriva Biologics media release, results of phase 1 trial of intravitreal VCN-01 in pediatric patients with refractory retinoblastoma will help inform the planned Phase 2 trial design.
30 Mar 2023 According to a Theriva Biologics media release, the company plans to hold a pre-IND meeting with the FDA (H2 2023) to discuss the clinical development and potential registration pathway for VCN-01 as an adjunct to chemotherapy in pediatric patients with advanced retinoblastoma.
11 Aug 2022 According to a Synthetic Biologics media release, the trial is expected to be initiated in the second half of 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com